Dr. Sundhar Ramalingam
Overview
I mainly treat patients with genitourinary cancers including prostate, kidney, bladder, testicular and penile cancer. My goal is to be attentive and devoted to my patients who are often dealing with complicated health problems. I try to personalize my care because every patient is different. I believe the future is promising because new treatments are being discovered every day. I am involved in clinical trials done through Duke University. Clinical trials are designed to provide patients with access to the newest possible treatments. I am also part of our multi-disciplinary cancer team including urologic oncologists, geneticists, radiation oncologists, pathologists, radiologists, and other specialists. I grew up in Cary and did all of my medical training in the Research Triangle Park area. I feel honored to practice in the same community I have lived in for more than twenty-five years.
Dr. Ramalingam is rated as an Experienced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, and Prostatectomy.
His clinical research consists of co-authoring 18 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Non-Small Cell Lung Cancer (NSCLC).
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- MEDICARE MAPD
- MEDICARE SNP
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- MEDICARE MAPD
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- HMO
- POS
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE ASSISTANCE PROGRAM
- MEDICARE MAPD
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- OTHER COMMERCIAL
- PPO
- EPO
- HMO
- POS
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
216 Ashville Ave, Cary, NC 27518
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Duke Cancer Center
When someone is faced with a diagnosis of lung cancer, they may be going through surgery, radiation treatment, chemotherapy or enrolling in a clinical trial. It’s a very complicated process to understand what’s involved and what may happen next. It’s also hard to hear all the answers if you’re by yourself. We encourage our patients to come with family members and friends and loved ones and particularly to identify one or two main go-to people in terms of care-giving and support. That way we can engage them in the whole process. Just as we have a team taking care of the patient, the patient has a team, too. At Duke, we have the opportunity to engage patients in the very latest treatment approaches, whether it’s a new surgical technique, the latest radiation approach, or some novel chemotherapy, immunology, or targeted therapy, several of which we’ve been developing. Duke provides patients with a real opportunity that they may not have elsewhere. Dr. Crawford is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.
Wakemed Specialists Group LLC
Praveen Namireddy is a Hematologist Oncology specialist and a Hematologist in Raleigh, North Carolina. Dr. Namireddy is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, and Lung Adenocarcinoma. Dr. Namireddy is currently accepting new patients.
Southeastern Medical Oncology Center
Samer Kasbari is a Hematologist Oncology specialist and a Hematologist in Goldsboro, North Carolina. Dr. Kasbari is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Colorectal Cancer, Small Cell Lung Cancer (SCLC), Endoscopy, and Bone Marrow Aspiration. Dr. Kasbari is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Chromophobe Renal Cell CarcinomaDr. Ramalingam isDistinguished. Learn about Chromophobe Renal Cell Carcinoma.
- Clear Cell SarcomaDr. Ramalingam isDistinguished. Learn about Clear Cell Sarcoma.
- Familial Prostate CancerDr. Ramalingam isDistinguished. Learn about Familial Prostate Cancer.
- Familial Wilms Tumor 2Dr. Ramalingam isDistinguished. Learn about Familial Wilms Tumor 2.
- Muscle Invasive Bladder CancerDr. Ramalingam isDistinguished. Learn about Muscle Invasive Bladder Cancer.
- Prostate CancerDr. Ramalingam isDistinguished. Learn about Prostate Cancer.
- Advanced
- Adult Soft Tissue SarcomaDr. Ramalingam isAdvanced. Learn about Adult Soft Tissue Sarcoma.
- Bladder CancerDr. Ramalingam isAdvanced. Learn about Bladder Cancer.
- ChoriocarcinomaDr. Ramalingam isAdvanced. Learn about Choriocarcinoma.
- Chronic T-Cell Leukemia (CTCL)Dr. Ramalingam isAdvanced. Learn about Chronic T-Cell Leukemia (CTCL).
- Large-Cell Immunoblastic LymphomaDr. Ramalingam isAdvanced. Learn about Large-Cell Immunoblastic Lymphoma.
- Lung CancerDr. Ramalingam isAdvanced. Learn about Lung Cancer.
- Experienced
- AgranulocytosisDr. Ramalingam isExperienced. Learn about Agranulocytosis.
- ALK-Positive Non-Small Cell Lung CancerDr. Ramalingam isExperienced. Learn about ALK-Positive Non-Small Cell Lung Cancer.
- Appendix CancerDr. Ramalingam isExperienced. Learn about Appendix Cancer.
- AstrocytomaDr. Ramalingam isExperienced. Learn about Astrocytoma.
- Atypical Teratoid Rhabdoid Tumor (ATRT)Dr. Ramalingam isExperienced. Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
- B-Cell LymphomaDr. Ramalingam isExperienced. Learn about B-Cell Lymphoma.